Patient (n = 344) and Breast Tumor Characteristics (n = 352)
| Characteristic | Data |
|---|---|
| Sex (total n, 344; 0 missing) | |
| Female | 341 (99.1%) |
| Male | 3 (0.9%) |
| Median age (y) | |
| Total patients (n, 344) | 59 (49–68) |
| <50-y age group (n, 97) | 45 (41–47) |
| ≥50-y age group (n, 247) | 63 (57–71) |
| BMI | |
| Total patients (n, 327; 14 missing) | 26.08 (23–29.52) |
| <50-y age group (n, 89; 8 missing) | 22.6 (20.50–26.17) |
| ≥50-y age group (n, 241; 6 missing) | 27 (24.22–30.15) |
| Tumor location (total n, 347; 5 missing) | |
| Upper outer quadrant | 115 (33.1%) |
| Upper inner quadrant | 38 (11%) |
| Lower inner quadrant | 19 (5.5%) |
| Lower outer quadrant | 24 (6.9%) |
| Central regions | 151 (43.5%) |
| Histologic subtype (total n, 351; 1 missing) | |
| Invasive ductal carcinoma | 253 (72.1%) |
| Invasive lobular carcinoma | 36 (10.3%) |
| Ductal carcinoma in situ | 19 (5.4%) |
| Others | 43 (12.3%) |
| Clinical T stage at diagnosis (total n, 351; 1 missing) | |
| T0 | 2 (0.6%) |
| T1 | 225 (64.1%) |
| T2 | 90 (25.6%) |
| T3 | 11 (3.1%) |
| T4 | 2 (0.6%) |
| Tis | 21 (6.0%) |
| Clinical N stage at diagnosis (total n, 348; 4 missing) | |
| Nx | 2 |
| N0 | 274 |
| N1 | 66 |
| N2 | 6 |
| Ki-67* | |
| Total patients (n, 332; 20 missing) | 12.50 (6.25–27.25) |
| <50-y age group (n, 95; 3 missing) | 20 (8.00–36.00) |
| ≥50-y age group (n, 237; 17 missing) | 12 (6.00–21.50) |
| Molecular subtype (total n, 334, 18 missing) | |
| Luminal A | 204 (61.1%) |
| Luminal B | 71 (21.3%) |
| HER-2 | 34 (10.2%) |
| Basallike | 25 (7.5%) |
| Neoadjuvant chemotherapy† (total n, 344; 0 missing) | |
| Yes | 45 (13.1%) |
| No | 299 (86.9%) |
| SLN pathology results (352 cases in 344 patients) | |
| Positive | 80 (22.8%) |
| Negative | 262 (74.4%) |
| Not harvested | 10 (2.8%) |